darlifarnib
dar-li-FAR-nib
Definition
An experimental cancer drug developed by Kura Oncology, currently being studied in combination with other targeted therapies for solid tumors like renal cell carcinoma and KRAS-mutant pancreatic cancer.
Etymology
This is a non-proprietary drug name (a generic name) created using standard pharmaceutical nomenclature, where the final suffix '-nib' denotes a kinase inhibitor, combined with a unique prefix (darli-) assigned by international naming authorities.
In the news
In the article, darlifarnib is presented as a secondary strategic asset in Kura Oncology's pipeline, which the company is advancing to diversify its portfolio beyond its lead menin inhibitor drug.
Earnings call transcript: Kura Oncology tops Q2 2026 estimates as launch gains
Read the full article ↗Investing.com